Introduction: Estrogen receptor-positive/HER2-negative breast cancer is the most common molecular subtype of breast cancer. Aromatase inhibitors such as letrozole are part of the standard endocrine treatment regimen for postmenopausal patients; however, real-world evidence on pat...
Open access
Research Article10.9734/jamps/2026/v28i8883
Background: Breast cancer remains the most common cancer among women worldwide and a major cause of preventable cancer mortality, particularly in resource-constrained settings where delayed presentation is common. Breast self-examination (BSE) does not replace clinical assessment...
Open access
Research Article10.9734/jamps/2026/v28i10895
Background: Gout is a disease caused by an overload of uric acid in the body, which leads to the formation of urate crystals that deposit in tissues, particularly in the joints. The deposition of these crystals causes recurring episodes of joint inflammation. This study aims to e...
Open access
Research Article10.9734/jamps/2025/v27i5777
Sara S. Abdelrahim, Mohammed H. Alnazeer, Mawahib A. Mustafa, Safa A. Abdalla, Elkhanssa Abdelhameed Ahmed Elhag, Kannan O. Ahmed, Yasir S. Kheir, Elmoiz Babekir & Bashir A. Yousef·Journal of Advances in Medical and Pharmaceutical Sciences·2026
Background: Imatinib mesylate is a tyrosine kinase inhibitor that has transformed the treatment of chronic myeloid leukaemia. However, information on its real-world use among sub-Saharan African populations remains limited. Aims: This study evaluated early haematological response...
Open access
Research Article10.9734/jamps/2026/v28i8879
Background: Tuberculosis (TB) is still one of the most important causes of morbidity and mortality worldwide. The problem multiplies whenever there is multidrug-resistant TB (MDR-TB), due to Mycobacterium tuberculosis susceptibility to both Rifampicin and Isoniazid. Pyrazinamide...
Open access
Research Article10.9734/jamps/2025/v27i12834